FDA ex­plains im­pact of Covid-19 on ap­pli­ca­tions, for­mal meet­ings

The FDA on Tues­day is­sued im­me­di­ate­ly ef­fec­tive guid­ance ex­plain­ing how the coro­n­avirus dis­ease pub­lic health emer­gency is im­pact­ing the con­duct of for­mal meet­ings and its re­view of cer­tain user fee-fund­ed ap­pli­ca­tions.

The guid­ance fea­tures 11 ques­tions and an­swers on how the agency in­tends to han­dle dis­rup­tions af­fect­ing meet­ings and goals un­der its user fee pro­grams es­tab­lished by the Pre­scrip­tion Drug User Fee Act (PDU­FA), Biosim­i­lar User Fee Act (BS­U­FA) and the Gener­ic Drug User Fee Amend­ments (GDU­FA).

Drug and bi­o­log­ics

FDA says its new drug and bi­o­log­ics pro­grams at the Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) and Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) are be­ing im­pact­ed by “con­sid­er­able in­creas­es in COVID-19 re­lat­ed work,” ne­ces­si­tat­ing shifts in re­sources and staff al­lo­ca­tion.

“With many staff mem­bers work­ing on COVID-19 ac­tiv­i­ties, it is pos­si­ble that we will not be able to sus­tain our cur­rent per­for­mance lev­el in meet­ing goal dates in­def­i­nite­ly,” FDA writes.

FDA says it will fo­cus its re­sources on ap­pli­ca­tions and sub­mis­sions re­lat­ed to Covid-19 and oth­er life-threat­en­ing con­di­tions and will “work di­rect­ly with the spon­sors and ap­pli­cants re­gard­ing their pend­ing ap­pli­ca­tions.”

FDA notes that it will still aim to con­duct ini­tial in­ves­ti­ga­tion­al new drug ap­pli­ca­tion (IND) 30-day safe­ty re­views and re­spond to “oth­er im­por­tant safe­ty is­sues that may emerge dur­ing IND de­vel­op­ment.”

FDA al­so ex­plains that it will com­mu­ni­cate di­rect­ly with spon­sors or ap­pli­cants if it an­tic­i­pates miss­ing a goal date, but notes that both the “PDU­FA and BS­U­FA goal let­ters do not con­tem­plate FDA ex­tend­ing or chang­ing user fee goal dates,” ex­cept in re­sponse to sub­mis­sion that would trig­ger a clock ex­ten­sion.

For­mal meet­ings

Dur­ing the pub­lic health emer­gency, FDA says that all meet­ings with in­dus­try will be held vir­tu­al­ly, via tele­con­fer­ence or video­con­fer­ence, not­ing that it has con­vert­ed many pre­vi­ous­ly sched­uled PDU­FA and BS­U­FA meet­ings from in-per­son to vir­tu­al at the same dates and times as orig­i­nal­ly sched­uled.

FDA says it is still ac­cept­ing new meet­ing re­quests “as per usu­al prac­tice,” but notes that it may pro­vide a writ­ten re­sponse on­ly in some cir­cum­stances and may reeval­u­ate the for­mat of some pend­ing meet­ings.

For ad­vi­so­ry com­mit­tee meet­ings, FDA says it is try­ing to fig­ure out whether meet­ings can be held vir­tu­al­ly on a case-by-case ba­sis.

“FDA is con­tin­u­ing to eval­u­ate the fea­si­bil­i­ty of con­duct­ing ad­vi­so­ry com­mit­tee meet­ings vir­tu­al­ly. We be­lieve we can host ad­vi­so­ry com­mit­tee meet­ings vir­tu­al­ly with cur­rent tech­nol­o­gy,” FDA says, but adds that it will dis­cuss the op­tion di­rect­ly with spon­sors and ap­pli­cants for spe­cif­ic ap­pli­ca­tions.

Gener­ic drugs

For the time be­ing, FDA says it is con­tin­u­ing its gener­ic drug pro­gram ap­pli­ca­tion as­sess­ment ac­tiv­i­ties but says that it “may need to shift re­sources to ad­dress ur­gent pub­lic health needs,” in re­sponse to short­ages.

How­ev­er, FDA in­structs gener­ic drug ap­pli­cants to con­tact the ap­pro­pri­ate project man­ag­er for their ap­pli­ca­tion if they “ex­pe­ri­ence a missed goal date.”

FDA notes that mid-re­view cy­cle meet­ings and post-com­plete re­sponse let­ter meet­ings are typ­i­cal­ly done via tele­con­fer­ence and adds up­com­ing face-to-face pre-ab­bre­vi­at­ed new drug ap­pli­ca­tion (AN­DA) meet­ings are be­ing con­vert­ed to tele­con­fer­ence. FDA says it will at­tempt to no­ti­fy ap­pli­cants at least four weeks in ad­vance of a meet­ing for­mat change.

FDA al­so says that it is pri­or­i­tiz­ing the re­view of AN­DAs ac­cord­ing to its re­cent­ly re­vised man­u­al of poli­cies and pro­ce­dures, which ex­plains that the agency will pri­or­i­tize AN­DAs for drugs that are in short­age, used to ad­dress the pub­lic health emer­gency or oth­er­wise meet the fac­tors for pri­or­i­ti­za­tion based on com­pe­ti­tion. FDA fur­ther ex­plains that it will con­sid­er “whether the AN­DA is for a drug be­ing in­ves­ti­gat­ed to treat or pre­vent Covid-19, but is not la­beled for this use, or for a drug be­ing used for its la­beled use to treat or pre­vent sec­ondary con­di­tions as­so­ci­at­ed with Covid-19.

In re­cent weeks FDA has an­nounced the ap­proval of sev­er­al AN­DAs for prod­ucts in short­age or sub­ject to in­creased de­mand amid the pub­lic health emer­gency, in­clud­ing hy­drox­y­chloro­quine sul­fate tablets, cisatracuri­um be­sy­late in­jec­tion, dexmedeto­mi­dine hy­drochlo­ride, suc­cinyl­choline chlo­ride in­jec­tion and azithromycin tablets.

FDA

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Pi­o­neer­ing Click Chem­istry in Hu­mans

Reimagining cancer treatments

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, which is nearly one in six deaths. Recently, we have seen incredible advances in novel cancer therapies such as immune checkpoint inhibitors, cell therapies, and antibody-drug conjugates that have revamped cancer care and improved survival rates for patients.

Despite this significant progress in therapeutic targeting, why are we still seeing such a high mortality rate? The reason is that promising therapies are often limited by their therapeutic index, which is a measure of the effective dose of a drug, relative to its safety. If we could broaden the therapeutic indices of currently available medicines, it would revolutionize cancer treatments. We are still on the quest to find the ultimate cancer medicine – highly effective in several cancer types, safe, and precisely targeted to the tumor site.

Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)

Ad­vo­cates, ex­perts cry foul over Amy­lyx's new ALS drug, cit­ing is­sues with price, PhI­II com­mit­ment

Not 24 hours after earning the first ALS drug approval in five years, Amylyx Pharmaceuticals’ Relyvrio is already drawing scrutiny. And it’s coming from multiple fronts.

In an investor call Friday morning, Amylyx revealed that it would charge about $158,000 per year, a price point that immediately drew backlash from ALS advocates and some outside observers. The cost reveal had been highly anticipated in the immediate hours after Thursday evening’s approval, though Amylyx only teased Relyvrio would cost less than previously approved drugs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

After brief stops in Paris and Boston, John Carroll and the Endpoints crew are staying on the road in October with their return for a live/streaming EUBIO22 in London. The hybrid event fireside chats and panels on mRNA, oncology and the crazy public market. We hope you can join him there.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Joshua Cohen (L) and Justin Klee, Amylyx co-CEOs

Up­dat­ed: Af­ter long and wind­ing road, FDA ap­proves Amy­lyx's ALS drug in vic­to­ry for pa­tients and ad­vo­ca­cy groups

For just the third time in its 116-year history, the FDA has approved a new treatment for Lou Gehrig’s disease, or ALS.

US regulators gave the thumbs-up to the drug, known as Relyvrio, in a massive win for patients and their families. The approval, given to Boston-area biotech Amylyx Pharmaceuticals, comes after two years of long and contentious debates over the drug’s effectiveness between advocacy groups and FDA scientists, following the readout of a mid-stage clinical trial in September 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Nooman Haque, head of life sciences and healthcare at Silicon Valley Bank, and John Carroll

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re staying on the road in October with our return for a live/streaming EUBIO22 in London.

Silicon Valley Bank’s Nooman Haque and I are once again jumping back into the thick of it with a slate of virtual and live events on October 12. I’ll get the ball rolling with a virtual fireside chat with Novo Nordisk R&D chief Marcus Schindler, covering their pipeline plans and BD work.

Up­dat­ed: Al­ny­lam re­in­forces APOL­LO-B patisir­an da­ta be­fore head­ing to the FDA

Weeks after uncorking some mostly positive data for patisiran in transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, Alnylam is bolstering its package with new exploratory and subgroup data before shipping it off to regulators.

The RNAi drug maintained “generally consistent” benefits in efficacy and quality of life across several prespecified subgroups at month 12, Alnylam announced on Friday afternoon, including age, baseline tafamidis use, ATTR amyloidosis type, baseline six-minute walk test score and others.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

#AAO22: J&J’s first look at com­mon eye dis­ease port­fo­lio pads the case for PhII of gene ther­a­py

CHICAGO — While the later-stage drug developers in the geographic atrophy field are near the finish line, Johnson & Johnson’s Janssen is taking a more deliberate route, with a treatment that it hopes to be a one-time fix.

The Big Pharma will take its Hemera Biosciences-acquired gene therapy into a Phase II study later this year in patients with GA, a common form of age-related macular degeneration that impacts about five million people worldwide. To get there, Janssen touted early-stage safety data at the American Academy of Ophthalmology annual conference Saturday morning, half a day after competitors Apellis and Iveric Bio revealed their own more-detailed Phase III analyses.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

In­dus­try groups call to block WTO IP waiv­er ex­pan­sion to Covid-19 ther­a­peu­tics

The WTO’s TRIPS Council in mid-October is expected to debate whether to extend the IP waiver for Covid-19 vaccines to therapeutics and diagnostics too.

While the Biden administration backed the original vaccine waiver, which critics note has not done much to expand access to vaccines as demand has dried up, US trade officials haven’t offered any perspective yet on whether to expand the waiver to Covid treatments.

Jerome Durso, Intercept Pharmaceuticals CEO

In­ter­cep­t's OCA fails a PhI­II NASH tri­al, rais­ing fresh doubts about its years­long quest for an OK

Intercept Pharmaceuticals has run into another big setback in its yearslong quest to win an approval for OCA in NASH. The biotech put out word Friday morning that its Phase III REVERSE study failed the primary endpoint for the liver disease, sending its share price into a tailspin.

There was no significant improvement in fibrosis among the patients suffering from cirrhosis who were treated with obeticholic acid, with investigators hunting for a minimum 1-stage histological improvement in the disease after 18 months of therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.